Christopher Raymond
Stock Analyst at Piper Sandler
(2.64)
# 2,034
Out of 5,122 analysts
139
Total ratings
52.63%
Success rate
1.32%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Upgrades: Overweight | $10 → $16 | $7.79 | +105.39% | 11 | Jan 9, 2026 | |
| LXEO Lexeo Therapeutics | Initiates: Strong Buy | $25 | $7.64 | +227.23% | 1 | Dec 18, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $4.66 | +178.97% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $7.82 | +271.08% | 2 | Oct 21, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $111.46 | -37.20% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $179.09 | -35.79% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.68 | +435.71% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $57.95 | +117.43% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $3.98 | +0.50% | 3 | Feb 11, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $220 → $227 | $225.64 | +0.60% | 12 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $535 → $533 | $472.01 | +12.92% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $755.02 | +34.17% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $24.76 | +465.43% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $65.48 | +9.96% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $3.61 | +260.11% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $6.31 | +1,088.59% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $11.75 | +546.81% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.28 | +3,497.12% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $31.02 | +6.38% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $37.96 | -42.04% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.38 | +189.86% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $344.68 | -16.44% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $28.16 | +45.60% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $45.94 | -39.05% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $104.85 | -61.85% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $6.43 | +1,299.69% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.70 | +5,547.06% | 2 | Mar 13, 2020 |
Ardelyx
Jan 9, 2026
Upgrades: Overweight
Price Target: $10 → $16
Current: $7.79
Upside: +105.39%
Lexeo Therapeutics
Dec 18, 2025
Initiates: Strong Buy
Price Target: $25
Current: $7.64
Upside: +227.23%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $4.66
Upside: +178.97%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $7.82
Upside: +271.08%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $111.46
Upside: -37.20%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $179.09
Upside: -35.79%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.68
Upside: +435.71%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $57.95
Upside: +117.43%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $3.98
Upside: +0.50%
AbbVie
Jan 27, 2025
Maintains: Overweight
Price Target: $220 → $227
Current: $225.64
Upside: +0.60%
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $472.01
Upside: +12.92%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $755.02
Upside: +34.17%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $24.76
Upside: +465.43%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $65.48
Upside: +9.96%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $3.61
Upside: +260.11%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $6.31
Upside: +1,088.59%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $11.75
Upside: +546.81%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.28
Upside: +3,497.12%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $31.02
Upside: +6.38%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $37.96
Upside: -42.04%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.38
Upside: +189.86%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $344.68
Upside: -16.44%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $28.16
Upside: +45.60%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $45.94
Upside: -39.05%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $104.85
Upside: -61.85%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $6.43
Upside: +1,299.69%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.70
Upside: +5,547.06%